{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T23:29:21Z","timestamp":1771457361587,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T00:00:00Z","timestamp":1537401600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81471392"],"award-info":[{"award-number":["81471392"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81671371"],"award-info":[{"award-number":["81671371"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1007\/s12020-018-1702-5","type":"journal-article","created":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T01:19:24Z","timestamp":1537406364000},"page":"464-469","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Cabergoline for the treatment of bromocriptine-resistant invasive giant prolactinomas"],"prefix":"10.1007","volume":"62","author":[{"given":"Hai Yan","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiwei","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guo Zhen","family":"Hui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhe Bao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,9,20]]},"reference":[{"issue":"1","key":"1702_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11102-005-5079-0","volume":"8","author":"A Ciccarelli","year":"2005","unstructured":"A. Ciccarelli, A.F. Daly, A. Beckers, The epidemiology of prolactinomas. Pituitary 8(1), 3 (2005)","journal-title":"Pituitary"},{"issue":"4","key":"1702_CR2","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/ncpendmet0160","volume":"2","author":"A Colao","year":"2006","unstructured":"A. Colao, S.A. Di, E. Guerra, L.M. De, A. Mentone, G. Lombardi, Drug insight: Cabergoline and bromocriptine in the treatment of hyperprolactinemia in men and women. Nat. Clin. Pract. Endocrinol. Metab. 2(4), 200\u2013210 (2006)","journal-title":"Nat. Clin. Pract. Endocrinol. Metab."},{"issue":"1","key":"1702_CR3","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3171\/jns.2006.104.1.54","volume":"104","author":"ZB Wu","year":"2006","unstructured":"Z.B. Wu, C.J. Yu, Z.P. Su, Q.C. Zhuge, J.S. Wu, W.M. Zheng, Bromocriptine treatment of invasive giant prolactinomas involving the cavernous sinus: results of a long-term follow up. J. Neurosurg. 104(1), 54\u201361 (2006)","journal-title":"J. Neurosurg."},{"issue":"6","key":"1702_CR4","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1530\/EJE-14-0013","volume":"170","author":"D Maiter","year":"2014","unstructured":"D. Maiter, E. Delgrange, Therapy of endocrine disease: the challenges in managing giant prolactinomas. Eur. J. Endocrinol. 170(6), 213\u2013227 (2014)","journal-title":"Eur. J. Endocrinol."},{"issue":"5","key":"1702_CR5","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1210\/er.2005-9998","volume":"27","author":"MP Gillam","year":"2006","unstructured":"M.P. Gillam, M.E. Molitch, G. Lombardi, A. Colao, Advances in the treatment of prolactinomas. Endocr. Rev. 27(5), 485\u2013534 (2006)","journal-title":"Endocr. Rev."},{"issue":"5","key":"1702_CR6","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.beem.2009.05.003","volume":"23","author":"A Colao","year":"2009","unstructured":"A. Colao, P. Chanson, The prolactinoma. Best. Pract. Res. Clin. Endocrinol. Metab. 23(5), 575\u2013596 (2009)","journal-title":"Best. Pract. Res. Clin. Endocrinol. Metab."},{"issue":"1","key":"1702_CR7","doi-asserted-by":"publisher","first-page":"42","DOI":"10.4158\/EP09221.OR","volume":"16","author":"SV Acharya","year":"2010","unstructured":"S.V. Acharya, R.A. Gopal, P.S. Menon, T.R. Bandgar, N.S. Shah, Giant prolactinoma and effectiveness of medical management. Endocr. Pract. 16(1), 42\u201346 (2010)","journal-title":"Endocr. Pract."},{"issue":"3","key":"1702_CR8","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1210\/jc.2012-3735","volume":"98","author":"XH Lou","year":"2013","unstructured":"X.H. Lou, Z.B. Wu, Y.Z. Zhang, Bromocriptine-induced brainstem angulation in a patient with invasive prolactinoma. J. Clin. Endocrinol. Metab. 98(3), 867\u2013868 (2013)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"5","key":"1702_CR9","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/nrendo.2011.37","volume":"7","author":"A Colao","year":"2011","unstructured":"A. Colao, S. Savastano, Medical treatment of prolactinomas. Nat. Rev. Endocrinol. 7(5), 267\u2013278 (2011)","journal-title":"Nat. Rev. Endocrinol."},{"issue":"3","key":"1702_CR10","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1210\/jcem.82.3.3822","volume":"82","author":"A Colao","year":"1997","unstructured":"A. Colao, A.D. Sarno, F. Sarnacchiaro, D. Ferone, G.D. Renzo, B. Merola, L. Annunziato, G. Lombardi, Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J. Clin. Endocrinol. Metab. 82(3), 876\u2013883 (1997)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"10","key":"1702_CR11","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1210\/jcem-60-4-698","volume":"40","author":"ME Molitch","year":"1985","unstructured":"M.E. Molitch, R.L. Elton, R.E. Blackwell, B. Caldwell, R.J. Chang, R. Jaffe, G. Joplin, R.J. Robbins, J. Tyson, M.O. Thorner, Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. J. Clin. Endocrinol. Metab. 40(10), 698\u2013705 (1985)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"5916","key":"1702_CR12","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1136\/bmj.2.5916.419","volume":"2","author":"MO Thorner","year":"1974","unstructured":"M.O. Thorner, A.S. Mcneilly, C. Hagan, G.M. Besser, Long-term treatment of galactorrhoea and hypogonadism with bromocriptine. Br. Med. J. 2(5916), 419\u2013422 (1974)","journal-title":"Br. Med. J."},{"issue":"4","key":"1702_CR13","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1530\/eje.0.1340454","volume":"134","author":"E Delgrange","year":"1996","unstructured":"E. Delgrange, D. Maiter, J. Donckier, Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine. Eur. J. Endocrinol. 134(4), 454 (1996)","journal-title":"Eur. J. Endocrinol."},{"issue":"7","key":"1702_CR14","doi-asserted-by":"publisher","first-page":"506","DOI":"10.3109\/09513590.2015.1017810","volume":"31","author":"A Capozzi","year":"2015","unstructured":"A. Capozzi, G. Scambia, A. Pontecorvi, S. Lello, Hyperprolactinemia: pathophysiology and therapeutic approach. Gynecol. Endocrinol. 31(7), 506\u2013510 (2015)","journal-title":"Gynecol. Endocrinol."},{"issue":"3","key":"1702_CR15","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1007\/s11011-018-0217-3","volume":"33","author":"Hai Yan Huang","year":"2018","unstructured":"H. Y. Huang, S. J. Lin, W. G. Zhao, Z. B. Wu, Cabergoline versus bromocriptine for the treatment of giant prolactinomas: a quantitative and systematic review. Metab. Brain Dis., 33(3), 969\u2013976 (2018)","journal-title":"Metabolic Brain Disease"},{"issue":"4","key":"1702_CR16","first-page":"610","volume":"33","author":"E Knosp","year":"1993","unstructured":"E. Knosp, E. Steiner, K. Kitz, C. Matula, Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 33(4), 610\u2013617 (1993)","journal-title":"Neurosurgery"},{"issue":"1","key":"1702_CR17","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/j.1365-2265.1991.tb01731.x","volume":"34","author":"L Duranteau","year":"2010","unstructured":"L. Duranteau, P. Chanson, A. Lavoinne, S. Horlait, J. Lubetzki, J.M. Kuhn, Effect of the new dopaminergic agonist CV 205\u2013502 on plasma prolactin levels and tumour size in bromocriptine\u2010resistant prolactinomas. Clin. Endocrinol. 34(1), 25\u201329 (2010)","journal-title":"Clin. Endocrinol."},{"issue":"5\u20136","key":"1702_CR18","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1159\/000182739","volume":"39","author":"R Razzaq","year":"1993","unstructured":"R. Razzaq, D.J. O\u2019Halloran, C.G. Beardwell, S.M. Shalet, The effects of CV205-502 in patients with hyperprolactinaemia intolerant and\/or resistant to bromocriptine. Horm. Res. 39(5\u20136), 218\u2013222 (1993)","journal-title":"Horm. Res."},{"issue":"1","key":"1702_CR19","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s11102-005-5085-2","volume":"8","author":"ME Molitch","year":"2005","unstructured":"M.E. Molitch, Pharmacologic resistance in prolactinoma patients. Pituitary 8(1), 43 (2005)","journal-title":"Pituitary"},{"issue":"11","key":"1702_CR20","doi-asserted-by":"publisher","first-page":"5256","DOI":"10.1210\/jcem.86.11.8054","volume":"86","author":"SA Di","year":"2001","unstructured":"S.A. Di, M.L. Landi, P. Cappabianca, S.F. Di, F.W. Rossi, R. Pivonello, S.C. Di, A. Faggiano, G. Lombardi, A. Colao, Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. J. Clin. Endocrinol. Metab. 86(11), 5256 (2001)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"1702_CR21","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s11060-013-1270-8","volume":"117","author":"ME Molitch","year":"2014","unstructured":"M.E. Molitch, Management of medically refractory prolactinoma. J. Neurooncol. 117(3), 421\u2013428 (2014)","journal-title":"J. Neurooncol."},{"key":"1702_CR22","doi-asserted-by":"crossref","unstructured":"E. Sbardella, G. Farah, A. Fathelrahman, S. Cudlip, O. Ansorge, N. Karavitaki, A. B. Grossman, A macroprolactinoma becoming resistant to cabergoline and developing atypical pathology. Endocrinol. Diabetes Metab. Case. Rep. 2016(1), pii:16-0038 (2016)","DOI":"10.1530\/EDM-16-0038"},{"issue":"6","key":"1702_CR23","first-page":"2247","volume":"85","author":"A Colao","year":"2000","unstructured":"A. Colao, S.A. Di, M.L. Landi, F. Scavuzzo, P. Cappabianca, R. Pivonello, R. Volpe, S.F. Di, S. Cirillo, L. Annunziato, Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. J. Clin. Endocrinol. Metab. 85(6), 2247\u20132252 (2000)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"14","key":"1702_CR24","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1056\/NEJM199410063311403","volume":"331","author":"J Webster","year":"1994","unstructured":"J. Webster, G. Piscitelli, A. Polli, C.I. Ferrari, I. Ismail, M.F. Scanlon, A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N. Engl. J. Med. 331(14), 904\u2013909 (1994)","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"1702_CR25","first-page":"2338","volume":"81","author":"BM Biller","year":"1996","unstructured":"B.M. Biller, M.E. Molitch, M.L. Vance, K.B. Cannistraro, K.R. Davis, J.A. Simons, J.R. Schoenfelder, A. Klibanski, Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. J. Clin. Endocrinol. Metab. 81(6), 2338\u20132343 (1996)","journal-title":"J. Clin. Endocrinol. Metab."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12020-018-1702-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-018-1702-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-018-1702-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T19:18:59Z","timestamp":1568920739000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12020-018-1702-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,20]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["1702"],"URL":"https:\/\/doi.org\/10.1007\/s12020-018-1702-5","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"value":"1355-008X","type":"print"},{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,20]]},"assertion":[{"value":"26 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}